Search Results - "Polychronopoulos, Georgios"

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience by Akinosoglou, Karolina, Rigopoulos, Emmanouil-Angelos, Kaiafa, Georgia, Daios, Stylianos, Karlafti, Eleni, Ztriva, Eleftheria, Polychronopoulos, Georgios, Gogos, Charalambos, Savopoulos, Christos

    Published in Viruses (30-12-2022)
    “…Effective treatments and vaccines against COVID-19 used in clinical practice have made a positive impact on controlling the spread of the pandemic, where they…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Treatment of heterozygous familial hypercholesterolemia: what does the future hold? by Polychronopoulos, Georgios, Tziomalos, Konstantinos

    Published in Expert review of clinical pharmacology (01-11-2020)
    “…Heterozygous familial hypercholesterolemia (heFH) is a common metabolic disease associated with increased cardiovascular risk. Despite treatment with the…”
    Get more information
    Journal Article
  7. 7

    Novel treatment options for the management of heterozygous familial hypercholesterolemia by Polychronopoulos, Georgios, Tziomalos, Konstantinos

    Published in Expert review of clinical pharmacology (02-12-2017)
    “…Even though statins represent the mainstay of treatment of heterozygous familial hypercholesterolemia (FH), their low-density lipoprotein cholesterol (LDL-C)…”
    Get more information
    Journal Article
  8. 8
  9. 9
  10. 10

    Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk by Erythropoulou-Kaltsidou, Anastasia, Polychronopoulos, Georgios, Tziomalos, Konstantinos

    Published in Diabetes therapy (01-01-2020)
    “…Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose…”
    Get full text
    Journal Article
  11. 11

    Heterozygous familial hypercholesterolemia: prevalence and control rates by Polychronopoulos, Georgios, Tzavelas, Marios, Tziomalos, Konstantinos

    “…: Heterozygous familial hypercholesterolemia (heFH) is associated with a very high risk for cardiovascular events. Treatment with potent statins substantially…”
    Get more information
    Journal Article
  12. 12

    Outcome‐Based Typology of Social Enterprises: Interlacing Individual Transformation, Capital Provision, and Societal Influence by Polychronopoulos, Georgios, Lukeš, Martin, Sansone, Giuliano, Agrawal, Anirudh, Ulrich‐Diener, Florian, Šlapáková Losová, Veronika

    Published in Journal of management studies (13-09-2024)
    “…Social entrepreneurship has emerged as a global phenomenon aimed at tackling societal grand challenges through market‐based activities. A holistic…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy by Kostourou, Danai-Thomais, Milonas, Dimitrios, Polychronopoulos, Georgios, Sofogianni, Areti, Tziomalos, Konstantinos

    Published in Journal of personalized medicine (30-07-2022)
    “…Neuropathy is a frequent complication of diabetes mellitus (DM) and is associated with the increased risk ofamputation and vascular events. Tight glycemic…”
    Get full text
    Journal Article
  19. 19
  20. 20